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Background: Autologous fat grafting is an emerging therapeutic option for cutaneous wounds. The regenerative
potential of autologous fat relates to the presence of adipose-derived stem cells (ADSCs) within the stromal vascular
fraction (SVF). ADSCs are capable of differentiating into fibroblasts and keratinocytes, as well as secreting soluble
mediators with angiogenic and anti-inflammatory properties. However, to date, there has been no comprehensive
assessment of the wound healing literature in humans. This systematic review aims to critically evaluate the efficacy
and safety of autologous fat grafting in acute and chronic cutaneous wounds with an appraisal of the quality of
evidence available.
Methods: Following PRISMA guidelines, MEDLINE, Embase and Cochrane Library databases will be searched from
inception to December 2017. All primary clinical studies in which wounds are treated with lipotransfer, cell-assisted
lipotransfer (CAL), SVF products or isolated ADSCs will be eligible for inclusion. Study screening and data extraction
will be conducted by two authors in duplicate. Our primary outcome measure will be the proportion of completely
healed wounds at 12 weeks. Secondary outcome measures will include the proportion of partially healed wounds at
12 weeks; the mean wound surface area reduction at 12 weeks; the mean time to wound healing; and adverse event
rates. The quality of evidence for each summary outcome measure will be assessed using the GRADE approach.
Discussion: In light of the growing popularity of autologous fat grafting for wound healing, a systematic appraisal of
the available evidence is timely. If autologous fat grafting is associated with a positive treatment effect, we will compare
these outcomes to those achieved using alternative wound management strategies. This review also aims to determine
if one or more autologous fat grafting techniques are superior and whether this varies according to patient- and
wound-specific factors. We anticipate that these results will guide future research and inform clinical practice.
Systematic review registration: PROSPERO CRD42017081499
Keywords: Adipose-derived stem cells, Autologous fat, Cell-assisted lipotransfer, Fat grafting, Lipotransfer, Stromal
vascular fraction, Wound healing, Ulcer, Systematic reviewBackground
There is growing interest in the regenerative potential of
autologous fat grafting (AFG). Adipose-derived stem cells
(ADSCs) contained within the stromal vascular fraction
(SVF) of lipoaspirate samples promote revascularisation,
activate local stem cell niches and modify immune re-
sponses via the paracrine secretion of numerous bioactive
molecules [1, 2]. They are also able to differentiate into
various terminal phenotypes that contribute to wound
healing, including fibroblasts and keratinocytes [3]. Unlike* Correspondence: joshua.luck1@nhs.net
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minimal donor site morbidity and used without ex vivo
culturing and expansion [4]. Autologous ADSCs do not
provoke a foreign body response, and they are found in the
greatest concentration of any MSCs in the body (up to 5000
cells may be isolated per gram of adipose tissue [3, 5]).
The most common method of AFG is based on the
Coleman technique [6]. Here, donor site lipoaspirate
samples are harvested and processed prior to injection
into a recipient site. The standard technique is referred
to as lipotransfer, although several variations exist. For
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Table 1 Electronic database search strategy
Free-text terms MeSH headings
fat graft* wound heal* Adipose tissue
fat transf* wound management Lipectomy
fat transplant* wound treat* Skin ulcer
fat inject* ulcer heal* Transplantation,
autologous
adipose graft* ulcer management* Wound healing
adipose stem cell* ulcer treat*
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ADSCs, preadipocytes, endothelial cells, haematopoetic-
lineage cells and fibroblasts [7]) or isolated ADSCs may en-
hance the regenerative potential of AFG [8]. This technique
is called cell-assisted lipotransfer (CAL). Alternatively, the
SVF cell pellet or a pure ADSC population may be injected
without lipoaspirate reconstitution [9–11]. There is no
consensus on the terminology for SVF- and ADSC-only
therapy; for the purposes of this review, we refer to these
approaches as SVF or ADSC monotherapy.
Although the early evidence for AFG for wound healing
is promising, much of the literature is based on animal
studies and there has been no comprehensive evaluation
of its efficacy and safety in humans. Similarly, there have
been no attempts made to systematically appraise the
quality of the evidence across the literature, despite the
growing popularity of AFG in the clinical setting [12].
Finally, there has been no comparative assessment of
the different AFG techniques for wound healing and it is
unclear whether one or more approaches are superior.
This systematic review aims to critically evaluate the
effectiveness and safety profile of AFG for acute and
chronic cutaneous wounds of any aetiology with an assess-
ment of the quality of the evidence available. It also seeks
to determine if any one AFG technique leads to better out-
comes and whether this differs according to either wound
or patient characteristics. A secondary objective will be to
compare AFG results to those obtained using alternative
wound management options.
Methods
This protocol has been prospectively registered on the
PROSPERO database (CRD42017081499) and will be
reported according to the Preferred Reporting Items
for Systematic Review and Meta-Analyses Protocols
(PRISMA-P) statement [13]. The final review will be
conducted and reported with reference to the PRISMA
statement [14]. In the event of no randomised controlled
trial (RCT) being included, additional consideration will
be given to the Meta-Analysis of Observational Studies in
Epidemiology (MOOSE) guidelines [15].
Search strategy
We will search MEDLINE, Embase and Cochrane Library
databases from inception to December 2017. Both free-
text terms and MeSH headings will be combined with
Boolean operators (see Table 1). A stepwise free-text
term serial search example is provided in the Appendix.
After removing duplicate citations, titles and abstracts
will be screened by two authors (DM and JL) in parallel.
The remaining articles will be read in full to shortlist arti-
cles for inclusion. The reference lists of all included studies
will be routinely checked to ensure that no relevant studies
have been missed. English language publications from anycountry of origin will be eligible for inclusion. Citations
will be managed using Mendeley (Elsevier, Amsterdam,
Netherlands) and Excel (Microsoft, Redmond, Washington,
USA).
Study selection criteria
All primary clinical studies using autologous fat therapy
for treating cutaneous wounds of any age will be eligible
for inclusion. For the purposes of this study, we define a
wound as any loss in epithelial continuity (with or without
involvement of underlying connective tissue). Healed scars
will not be considered as wounds.
Participants
Randomised controlled and observational studies conducted
in any clinical setting involving three or more adult partici-
pants (aged between 18 and 90 years old) will be eligible for
inclusion. No restrictions will be applied to the following:
wound aetiology, wound size, wound chronicity or number
of wounds per patient. Case reports, letters, editorials, con-
ference abstracts and literature reviews will be excluded.
Intervention
All methods in which autologous fat or its derivatives
are applied to a wound will be deemed eligible for inclusion.
AFG interventions will include conventional fat grafting
(lipotransfer), CAL and isolated ADSC or SVF monother-
apy. No restrictions will be applied to the following: fat
harvesting technique, fat processing methodology, in vitro
cell expansion, number of interventions or wound bed
preparation. All adjunct therapies will be included, with the
exception of platelet-rich plasma (PRP) as this has already
been reviewed by our research group (in press). Studies in
which PRP and autologous fat are co-administered will be
excluded from this review.
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All experimental studies evaluating AFG either in isola-
tion, in conjunction or in comparison to any other wound
management option will be eligible for inclusion. We
intend to compare AFG outcomes with alternative wound
management options. However, to avoid misleading cross-
comparative evaluation of the literature, we will only
extract data from comparator interventions or controls
when these have been conducted in parallel with and directly
compared to an AFG treatment arm.
Outcome
Studies reporting on any clinically relevant outcome at
any length of follow-up will be eligible for inclusion.
Ongoing and unpublished studies will be excluded.
Data extraction
Data collection and analysis will be completed as per the
Cochrane Handbook of Systematic Reviews of Interventions
[16]. All data will be extracted onto a pre-designed elec-
tronic form in duplicate by two authors (JL and DM) to
ensure accuracy. Any disagreements will be resolved by
discussion and consensus with referral to a third review
team member (OJS) as necessary.
Data items will relate to the following:
1. Study design and patient demographics
2. Pre-intervention wound characteristics
3. Autologous fat therapy methodology
4. Post-intervention wound healing outcomes
Where studies provide information on multiple different
interventions, data will be extracted for those related to
the current research objective only. Where appropriate,
authors will be contacted to provide missing information.
The unit of analysis will be individual wounds. For
example, if AFG is used to treat multiple wounds on
the same patient, data will be extracted per wound.
Outcome measures
Our primary outcome will be the proportion of com-
pletely healed wounds at 12 weeks.
Secondary outcome measures will include the propor-
tion of partially healed wounds at 12 weeks (defined as a
1–99% reduction in wound surface area); the mean wound
surface area reduction at 12 weeks (as a percentage change
from baseline); the time to complete wound healing (de-
fined as complete re-epithelialisation); and adverse event
rates (related to either donor or recipient sites).
If three or more included studies report on either
economic or health-related quality of life outcomes, we
will extract these data and comment on its implications
in the qualitative synthesis.Subgroup analyses
Subgroup analyses will be performed to further interro-
gate primary and/or secondary outcomes based on wound
aetiology (e.g. diabetic wounds, traumatic wounds, venous
wounds, arterial wounds, neuropathic wounds, burn
wounds) and chronicity (with acute defined as < 3 months
and chronic > 3 months duration) providing sufficient
data are available.
To ascertain if any single method of AFG is superior,
we will present data according to the intervention type
used (i.e. lipotransfer, CAL, SVF- or ADSC-only groups).Risk of bias assessment
We anticipate that all included studies will use an obser-
vational study design. Risk of bias for each study will
therefore be assessed using the ROBINS-I tool [17].
However, if any randomised controlled trials (RCTs) are
included, these will also be further assessed on a per
study basis using the Cochrane Collaboration Risk of
Bias Assessment Tool [18].
Two authors (JL and DM) will independently appraise
the quality of evidence across all included studies for
each outcome of interest using the Grading of Recom-
mendations, Assessment, Development and Evaluation
(GRADE) approach [19]. Any discrepancies will be re-
solved by discussion and consensus or referral to a third
team member (OJS or AM) as necessary.Data analysis and synthesis
Primary and secondary outcome measures will be evaluated
using simple descriptive statistics. Where appropriate, we
will provide pooled estimates with corresponding measures
of dispersion.
We will only perform a meta-analysis if a sufficient
number of studies (minimum ≥ 3) with consistent charac-
teristics are included. In the first instance, we will combine
all AFG techniques into a single intervention group. If
≥ 3 comparable studies are available for one or more
intervention subtypes (namely lipotransfer, CAL, SVF- or
ADSC-only), we will perform individual subgroup meta-
analyses to statistically evaluate how these techniques
compare to one another.
We will explore all sources of potential heterogeneity
related to study design, participants, interventions, com-
parators and outcomes. Statistical heterogeneity will be
assessed using the chi-square test and quantified with
the I2 statistic. The thresholds for interpretation of the I2
value will be in accordance with those presented in the
Cochrane Handbook for Systematic Reviews of Interven-
tions [16]. An evaluation of between study heterogeneity
will inform our decision as to whether a fixed or random
effects model is more appropriate for the dataset. If suf-
ficient studies are included in the meta-analysis, we will
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using a sensitivity analysis [20].
Continuous outcomes will be analysed using either
mean differences or standardised mean differences (with
95% confidence intervals (CIs)); dichotomous data will be
analysed using risk ratios (with 95% CIs); time-to-event
data will be analysed using hazard ratios (with 95% CIs).
In the event that a meta-analysis is not appropriate, we
will combine the results of all included studies in a qualita-
tive synthesis with reference to our primary and secondary
outcomes. In this narrative evaluation, we will comment on
whether the efficacy and safety of AFG appears to vary
according to the intervention subgroups defined above.
Discussion
In light of the growing popularity of autologous fat graft-
ing for wound healing, a systematic appraisal of the
available evidence is timely. Although preclinical studies
in both animal and in vitro models are encouraging,
whether AFG improves wound healing outcomes in the
clinical setting has yet to be conclusively established.
Should AFG be observed to improve wound healing, we
hope to identify which technique is superior and whether
this varies according to patient- and wound-specific fac-
tors. Similarly, we hope to draw meaningful comparisons
between AFG interventions and alternative wound manage-
ment options in an attempt to demonstrate which approach
is more effective. Together, these findings should help
inform clinical practice when selecting the optimal treat-
ment modality on a case-by-case basis.
We will qualify the strength of our conclusions using a
robust and validated methodology for appraising the
quality of evidence for each summary outcome measure.
We will discuss all relevant methodological issues and
areas of uncertainty within the current literature with
the intention that these observations are able to guide
future research.Appendix
Table 2 Example free-text term stepwise search strategy
Search 1 (fat graft* OR fat transf* OR fat inject*) AND (wound heal*
OR wound management OR wound treat*)
Search 2 (adipose graft* OR adipose stem cell* OR adipose derived
stem cell* OR ASC* OR ADSC*) AND (wound heal* OR
wound management OR wound treat*)
Search 3 (lipofill* OR lipotransf* OR lipomodell*) AND (wound heal*
OR wound management OR wound treat*)
Search 4 (fat graft* OR fat transf* OR fat inject*) AND (ulcer heal*
OR ulcer management OR ulcer treat*)
Search 5 (adipose graft* OR adipose stem cell* OR adipose derived
stem cell* OR ASC* OR ADSC*) AND (ulcer heal* OR ulcer
management OR ulcer treat*)
Search 6 (lipofill* OR lipotransf* OR lipomodell*) AND (ulcer heal*
OR ulcer management OR ulcer treat*)Abbreviations
ADSC: Adipose derived stem cell; AFG: Autologous fat grafting;
CAL: Cell-assisted lipotransfer; CI: Confidence interval; CONSORT: Consolidated
Standards of Reporting Trials; GRADE: Grading of Recommendations,
Assessment, Development and Evaluation; MeSH: Medical Subject Headings;
MSC: Mesenchymal stem cell; MOOSE: Meta-Analysis of Observational Studies in
Epidemiology; PRISMA: Preferred Reporting Items for Systematic Reviews and
Meta-Analyses; PRP: Platelet-rich plasma; RCT: Randomised control trial;
SVF: Stromal vascular fraction
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